SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose 9.2% Stake in Monte Rosa Therapeutics

Multiple entities associated with Biotechnology Value Fund, including Mark N. Lampert, have collectively disclosed a beneficial ownership of 9.2% in Monte Rosa Therapeutics, Inc. as of March 31, 2025.

Summary

• As of March 31, 2025, Biotechnology Value Fund, L.P. (BVF) beneficially owned 2,909,511 shares, representing approximately 4.7% of Monte Rosa Therapeutics' outstanding common stock.
• Biotechnology Value Fund II, L.P. (BVF2) beneficially owned 2,347,693 shares, equating to approximately 3.8% of the outstanding shares.
• Biotechnology Value Trading Fund OS LP beneficially owned 293,594 shares, representing approximately 0.5% of the outstanding shares.
• BVF GP Holdings LLC (BVF GPH) is deemed to beneficially own 5,257,204 shares, or approximately 8.5%, which aggregates the holdings of BVF and BVF2.
• BVF Partners L.P., BVF Inc., and Mark N. Lampert are each deemed to beneficially own 5,660,132 shares, representing approximately 9.2% of the outstanding shares, encompassing the holdings of BVF, BVF2, Trading Fund OS, and 109,334 shares held in a Partners managed account.
• The percentages are based on 61,509,821 shares outstanding as of March 17, 2025, as reported in Monte Rosa Therapeutics' Annual Report on Form 10-K filed on March 20, 2025.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without expressing positive or negative sentiment about the company's performance or prospects.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance regarding the issuer's future performance.

Industry Context

This Schedule 13G filing indicates a significant passive investment by a specialized biotechnology investment fund in Monte Rosa Therapeutics, a company operating within the biotechnology sector. Such disclosures are common for institutional investors accumulating positions in public companies, particularly in growth-oriented sectors like biotech, and provide transparency regarding major shareholder interests.

Related Party Transactions

• The various Biotechnology Value Fund entities and Mark N. Lampert are interconnected through general partnership, investment management, and directorship roles, leading to shared voting and dispositive power over the reported shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially signal confidence or a strategic interest in the company.
• Management: Awareness of a large, concentrated ownership by a specialized fund may influence strategic decisions, although the filing states the shares are not held for control purposes beyond potential nominations.

Key Dates

Keywords

Monte Rosa Therapeutics, Biotechnology Value Fund, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotech, Investment Management, Shareholder Disclosure